Poxel SA
7PO
Company Profile
Business description
Poxel SA is a biopharmaceutical company. It is focused on the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as nonalcoholic steatohepatitis (NASH) and rare disorders (ALD/AMN). It has developed a portfolio of drug candidates, including its candidates: Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH.
Contact
259/261 Avenue Jean Jaures
Immeuble le Sunway
Lyon69007
FRAT: +33 437372010
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
5
Stocks News & Analysis
stocks
Why Morningstar thinks Anthropic is worth $1.7 trillion
A look at how we arrive at our base-case valuation for the AI lab, along with bull and bear scenarios.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,265.60 | 102.20 | 1.12% |
| CAC 40 | 8,233.30 | 94.30 | 1.16% |
| DAX 40 | 26,267.19 | 446.83 | 1.73% |
| Dow JONES (US) | 52,389.75 | 1,104.02 | 2.15% |
| FTSE 100 | 10,782.87 | 108.93 | 1.02% |
| HKSE | 24,448.95 | 32.91 | -0.13% |
| NASDAQ | 25,253.14 | 673.71 | 2.74% |
| Nikkei 225 | 60,313.78 | 1,538.28 | 2.62% |
| NZX 50 Index | 14,111.45 | 137.83 | 0.99% |
| S&P 500 | 7,549.94 | 173.08 | 2.35% |
| S&P/ASX 200 | 9,131.30 | 101.60 | 1.13% |
| SSE Composite Index | 3,660.74 | 0.05 | -0.00% |